MD4481C1 - Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV - Google Patents

Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV

Info

Publication number
MD4481C1
MD4481C1 MDA20120127A MD20120127A MD4481C1 MD 4481 C1 MD4481 C1 MD 4481C1 MD A20120127 A MDA20120127 A MD A20120127A MD 20120127 A MD20120127 A MD 20120127A MD 4481 C1 MD4481 C1 MD 4481C1
Authority
MD
Moldova
Prior art keywords
khv
prevention
vaccine
koi herpesvirus
disease caused
Prior art date
Application number
MDA20120127A
Other languages
English (en)
Russian (ru)
Other versions
MD4481B1 (ro
MD20120127A2 (ro
Inventor
Алайн Францис Клод0 ВАНДЕРПЛАСШЕН
Original Assignee
Gesval S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gesval S.A. filed Critical Gesval S.A.
Publication of MD20120127A2 publication Critical patent/MD20120127A2/ro
Publication of MD4481B1 publication Critical patent/MD4481B1/ro
Publication of MD4481C1 publication Critical patent/MD4481C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

Invenţia se referă la un herpesvirus atenuat recombinant viu Koi (KHV) şi poate fi utilizată pentru profilaxia şi/sau tratamentul terapeutic al bolii peştilor cauzate de herpesvirusul Koi la crapi, aşa ca Cyprinos carpio carpio sau Cyprinos carpio koi.Conform invenţiei, herpesvirusul menţionat conţine o genă, în care cadrul de citire deschis 56 (ORF56) şi cadrul de citire deschis 57 (ORF57) au fost supuse mutaţiei. De asemenea, invenţia se referă la o metodă de obţinere a acestui tip de KHV, la celule ce conţin aşa KHV şi la utilizarea acestui KHV în calitate de vector şi în vaccinuri.Secvenţe: 12
MDA20120127A 2011-12-30 2012-12-27 Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV MD4481C1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11196171 2011-12-30

Publications (3)

Publication Number Publication Date
MD20120127A2 MD20120127A2 (ro) 2013-07-31
MD4481B1 MD4481B1 (ro) 2017-05-31
MD4481C1 true MD4481C1 (ro) 2017-12-31

Family

ID=47429841

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120127A MD4481C1 (ro) 2011-12-30 2012-12-27 Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV

Country Status (18)

Country Link
US (2) US20140348875A1 (ro)
EP (1) EP2797627B1 (ro)
JP (3) JP5982009B2 (ro)
CN (1) CN104159609B (ro)
BR (1) BR112014016117A2 (ro)
HU (1) HUE053075T2 (ro)
IL (1) IL232902A0 (ro)
IN (1) IN2014CN04655A (ro)
MD (1) MD4481C1 (ro)
MX (1) MX361408B (ro)
PH (1) PH12014501388A1 (ro)
PL (1) PL2797627T3 (ro)
RS (1) RS61261B1 (ro)
RU (1) RU2662768C2 (ro)
SG (1) SG11201403066TA (ro)
TW (1) TWI484034B (ro)
UA (2) UA114719C2 (ro)
WO (1) WO2013098214A1 (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662768C2 (ru) * 2011-12-30 2018-07-31 Гесвал с.а. Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv
WO2017177071A1 (en) * 2016-04-08 2017-10-12 William Marsh Rice University Improved galactose utilization
RU2736472C2 (ru) * 2016-11-18 2020-11-17 Общество с ограниченной ответственностью "ЭКСИФАРМ" Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк
CN112279897B (zh) * 2018-11-05 2021-12-28 深圳技术大学 一种预防或治疗鱼类感染CyHV-2的试剂及应用
EP3662929A1 (en) * 2018-12-07 2020-06-10 IDT Biologika GmbH A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv
CN110101854B (zh) * 2019-05-14 2022-08-02 四川农业大学 一种鲤疱疹病毒ⅲ型疫苗及其制备方法
CN110468111B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN110452926B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN113679832A (zh) * 2021-05-24 2021-11-23 苏州大学 一种利用冷冻干燥制备杆状病毒载鲤疱疹病毒ii型dna疫苗的方法
CN115960903B (zh) * 2022-12-23 2023-09-08 中国水产科学研究院淡水渔业研究中心 一种抑制CyHV-2病毒增殖的反义RNA组、重组载体和纳米粒递送系统及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061093A1 (en) * 2003-01-01 2004-07-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Immunizing fish against viral infection
WO2009027412A1 (en) * 2007-08-28 2009-03-05 Universite De Liege A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
JP2007223913A (ja) * 2006-02-21 2007-09-06 Kyoritsu Seiyaku Kk コイヘルペスウイルス病ワクチン
JP5239023B2 (ja) * 2006-04-13 2013-07-17 国立大学法人東京海洋大学 コイヘルペスウイルス（ｋｈｖ）病用ｄｎａワクチン
DE102007041332A1 (de) * 2007-08-31 2009-03-05 Siemens Ag Transferchuck zur Übertragung, insbesondere von Wafern
RU2662768C2 (ru) * 2011-12-30 2018-07-31 Гесвал с.а. Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061093A1 (en) * 2003-01-01 2004-07-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Immunizing fish against viral infection
WO2009027412A1 (en) * 2007-08-28 2009-03-05 Universite De Liege A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Borst E., Hahn G., Koszinowski U. & Messerle M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol., nr. 73, 1999, p. 8320-8329 *
Costes B et al. Cloning of the koi herpesvirus genome as an infectious bacterial artificial chromosome demonstrates that disruption of the thymidine kinase locus induces partial attenuation in Cyprinus carpio koi. J. of Virology, The American Society for microbiology, US, vol. 82, no.10, 2008.05.01, p. 4955-4964 *
Krzysztof L., Rakus et al. gene expression analysis of common carp (Cyprinus carpio L.) lines during Cyprinid herpesvirus 3 infection yields insights into differential immune responses. Developmental &Comparative Immunology, vol. 37, no. 1, 2011.12.24, p. 65-76 *
Messerle M., Crnkovic I., Hammerschmidt W., Ziegler H. & Koszinowski U. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA, nr. 94,1997, p. 14759-14763 *

Also Published As

Publication number Publication date
RS61261B1 (sr) 2021-01-29
MD4481B1 (ro) 2017-05-31
MX361408B (es) 2018-12-04
JP5982009B2 (ja) 2016-08-31
CN104159609B (zh) 2018-05-22
TWI484034B (zh) 2015-05-11
RU2662768C2 (ru) 2018-07-31
EP2797627A1 (en) 2014-11-05
CN104159609A (zh) 2014-11-19
EP2797627B1 (en) 2020-10-07
PH12014501388A1 (en) 2014-09-22
JP2016195593A (ja) 2016-11-24
US20140348875A1 (en) 2014-11-27
JP2018078903A (ja) 2018-05-24
IN2014CN04655A (ro) 2015-09-18
IL232902A0 (en) 2014-07-31
TW201333201A (zh) 2013-08-16
MD20120127A2 (ro) 2013-07-31
JP2015503914A (ja) 2015-02-05
BR112014016117A2 (pt) 2018-09-25
US9931396B2 (en) 2018-04-03
HUE053075T2 (hu) 2021-06-28
UA114719C2 (uk) 2017-07-25
PL2797627T3 (pl) 2021-06-28
UA119786C2 (uk) 2019-08-12
WO2013098214A1 (en) 2013-07-04
US20170028057A1 (en) 2017-02-02
RU2014131474A (ru) 2016-02-20
MX2014008045A (es) 2014-10-24
SG11201403066TA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
MD4481C1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
NZ708144A (en) Recombinant adenoviruses and use thereof
SG10201907775QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
IN2014DN05670A (ro)
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
WO2010033798A3 (en) Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
HUE055070T2 (hu) Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
EP2528931A4 (en) CYCLOVIRUS AND USE METHOD THEREFOR
NZ603442A (en) Treatment of proliferative diseases
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
GB201104897D0 (en) Method for the production of protein complexes and vaccine compositions comprising the same
WO2012149525A3 (en) Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection
WO2010147971A3 (en) Il23 modified viral vector for recombinant vaccines and tumor treatment
TH158445A (th) รีคอมบิแนนท์คอยเฮอร์ปีส์ไวรัส (khv) และวัคซีนสำหรับการป้องกันของโรคที่ได้รับการทำให้เกิดขึ้นโดย khv
UA99801C2 (ru) Белковая конструкция, которая включает модифицированный полипептид casb7439

Legal Events

Date Code Title Description
GB9A Change of applicant (patent for invention)

Owner name: GESVAL S.A., BE AVENUE PRE-AILY, 4, B-4031 ANGLEUR

Free format text: PREVIOUS APPLICANT: UNIVERSITE DE LIEGE, BE AVENUE PRE-AILY, 4, B-4031 ANGLEUR, BELGIA

FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees